Find where to buy products from suppliers in the USA, including: distributors, industrial manufacturers in America, bulk supplies and wholesalers of raw ingredients & finished goods.
Search for products or services, then visit the American suppliers website for prices, SDS or more information. You can also view suppliers in Australia, NZ or the UK.
| Product | Description | |
|---|---|---|
| FLT3 Inhibitor III | FLT3 Inhibitor III, a cell-permeable 5-phenyl-2-thiazolamine compound, is a potent inhibitor of Fms-like tyrosine kinase 3 (FLT3) with an IC50 of 50 nM. It displays high selectivity for FLT3 over a panel of 300 other kinases. Synonyms: Fms-like Tyrosine Kinase Inhibitor III; (5-Phenyl-thiazol-2-yl)-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-amine; 5-Phenyl-N-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-thiazolamine; 5-Phenyl-N-(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-2-thiazolamine; (5-Phenyl-thiazol-2-yl)-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-amine. Grades: ≥98%. CAS No. 852045-46-6. Molecular formula: C21H23N3OS. Mole weight: 365.5. |  |
| Flt3 Inhibitor IV - CAS 819058-89-4 | The Flt3 Inhibitor IV, also referenced under CAS 819058-89-4, controls the biological activity of Flt3. Group: Fluorescence/luminescence spectroscopy. |  |
| 4SC-203 | 4SC-203 is a multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. FLT3 (FLK2), a class III tyrosine kinase receptor, is overexpressed or mutated in most B lineage and acute myeloid leukemias (AML). VEGFRs, tyrosine kinase receptors, are overexpressed in a variety of tumor cell types and play key roles in angiogenesis. Uses: Designed for use in research and industrial production. Additional or Alternative Names: 4SC203; 4SC-203; 4SC 203; SC71710; SC-71710; SC 71710. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 895533-09-2. Molecular formula: C33H38N8O4S. Mole weight: 642.77. Purity: >98%. IUPACName: 1-(2-methoxy-5-methylphenyl)-3-(6-((6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinazolin-4-yl)amino)benzo[d]thiazol-2-yl)urea. Canonical SMILES: O=C(NC1=NC2=CC=C(NC3=C4C=C(OC)C(OCCCN5CCN(C)CC5)=CC4=NC=N3)C=C2S1)NC6=CC(C)=CC=C6OC. Product ID: ACM895533092. Alfa Chemistry ISO 9001:2015 Certified. |  |
| 4SC-203 | 4SC-203 is a multikinase inhibitor with potential antineoplastic activity. Multikinase inhibitor 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). This may result in the inhibition of angiogenesis and cell proliferation in tumor cells in which these kinases are upregulated. Synonyms: 4SC-203; 4SC 203; 4SC203; SC71710; SC-71710; SC 71710. Grades: 98%. CAS No. 895533-09-2. Molecular formula: C33H38N8O4S. Mole weight: 642.78. | |
| 5'-Fluoroindirubinoxime | 5'-Fluoroindirubinoxime is an inhibitor of FMS-like receptor tyrosine kinase-3 (FLT3) (IC50 = 15 nM) with antiproliferative activity. It displays selectivity for FLT3 against 6 other kinases including EGFR. Synonyms: 5'-Fluoro-1H,1'H-[2,3']biindolylidene-3,2'dione 3-oxime. Grades: ≥99% by HPLC. CAS No. 861214-33-7. Molecular formula: C16H10FN3O2. Mole weight: 295.27. | |
| AAE871 | AAE871 is a type I FLT3 inhibitor. Synonyms: AAE-871; AAE 871; 9H-Purine-2,6-diamine, N2-(trans-4-aminocyclohexyl)-9-ethyl-N6-[4-(1-piperidinylsulfonyl)phenyl]-. Grades: >98%. CAS No. 289479-07-8. Molecular formula: C24H34N8O2S. Mole weight: 498.64. | |
| AC 220 | AC 220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). Group: Biochemicals. Grades: Highly Purified. CAS No. 950769-58-1. Pack Sizes: 10mg, 50mg. Molecular Formula: C29H32N6O4S. US Biological Life Sciences. |  Worldwide |
| AC 220 dihydrochloride | AC 220 dihydrochloride is a potent and selective inhibitor of FMS-like tyrosine kinase-3 (FLT3) used for the treatment of AML. Uses: The treatment of aml. Synonyms: AC 220 dihydrochloride; AC220 dihydrochloride; AC-220 dihydrochloride; Quizartinib dihydrochloride; 1-(5-tert-butyl-1,2-oxazol-3-yl)-3-[4-[6-(2-morpholin-4-ylethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea dihydrochloride. Grades: 98%. CAS No. 1132827-21-4. Molecular formula: C29H32N6O4S.2HCl. Mole weight: 633.59. | |
| AC710 | AC710 is a potent PDGFR inhibitor with K d s of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 1351522-04-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13493. |  |
| AC710 Mesylate | AC710 Mesylate is a potent, selective PDGFR-family kinases inhibitor with Kd values of 0.6 nM/1.0 nM/1.3 nM/1.0 nM for FLT3/KIT/PDGFRα/PDGFRβ respectively. Synonyms: AC710 Mesylate; AC 710 Mesylate; AC-710 Mesylate. Grades: >98%. CAS No. 1351522-05-8. Molecular formula: C32H46N6O7S. Mole weight: 658.81. | |
| AFG206 | AFG206 is the novel first-generation "type II" FLT3 inhibitor. Synonyms: AFG-206; AFG 206. Grades: >98%. CAS No. 630122-37-1. Molecular formula: C20H19N3O2. Mole weight: 333.38. | |
| AFG210 | AFG210 is a novel first-generation "type II" FLT3 inhibitor. Synonyms: AFG 210; AFG-210; 1-(3-(trifluoromethyl)phenyl)-3-(4-(pyridin-4-yloxy)phenyl)urea. Grades: >98%. CAS No. 228400-22-4. Molecular formula: C19H14F3N3O2. Mole weight: 373.33. | |
| AKN-028 | AKN-028, the FLT3/KIT kinase inhibitor, is an orally bioavailable protein tyrosine kinase inhibitor for FMS-related tyrosine kinase 3 (FLT3; STK1) and stem cell factor receptor (SCFR; KIT), with potential antineoplastic activity. FLT3/KIT kinase inhibitor AKN-028 binds to and inhibits both the wild-type and mutated forms of FLT3 and SCFR. This may result in an inhibition of tumor cell proliferation in cancer cell types that overexpress these receptor tyrosine kinases. Synonyms: AKN 028; AKN028; N2-(1H-Indol-5-yl)-6-(pyridin-4-yl)pyrazine-2,3-diamine; 2,3-Pyrazinediamine, N3-1H-indol-5-yl-5-(4-pyridinyl)-; N3-(1H-Indol-5-yl)-5-(4-pyridinyl)-2,3-pyrazinediamine. Grades: ≥95%. CAS No. 1175017-90-9. Molecular formula: C17H14N6. Mole weight: 302.33. | |
| AMG 925 | AMG-925 is a potent, selective, and bioavailable FLT3/cyclin-dependent kinase 4 (CDK4) dual kinase inhibitor. AMG 925 inhibited AML xenograft tumor growth by 96% to 99% without significant body weight loss. The antitumor activity of AMG 925 correlated with the inhibition of STAT5 and RB phosphorylation, the pharmacodynamic markers for inhibition of FLT3 and CDK4, respectively. In addition, AMG 925 was also found to inhibit FLT3 mutants (e.g., D835Y) that are resistant to the current FLT3 inhibitors (e.g., AC220 and sorafenib). AMG 925, which combines inhibition of two kinases essential for proliferation and survival of FLT3-mutated AML cells, may improve and prolong clinical responses. Synonyms: AMG925; AMG-925; AMG 925; FLX925; FLX-925; FLX 925. Grades: >98%. CAS No. 1401033-86-0. Molecular formula: C26H29N7O2. Mole weight: 471.55. | |
| AST 487 | AST487 is a Ret kinase inhibitor/FLT3 inhibitor, which displays high selectivity and potency toward FLT3 as a molecular target, and which could potentially be used to override drug resistance in AML. It induced a dose-dependent growth inhibition of xenografts of NIH3T3 cells expressing oncogenic RET, and of the MTC cell line TT in nude mice.It also inhibited calcitonin gene expression in vitro in TT cells, in part, through decreased gene transcription. Synonyms: NVP-AST 487; NVPAST487; AST 487; AST487; AST-487. Grades: >98%. CAS No. 630124-46-8. Molecular formula: C26H30F3N7O2. Mole weight: 529.56. | |
| AST-487 | Potent RET kinase inhibitor. AST 487 displays high selectivity and potency toward FLT3 as a molecular target, and which could potentially be used to override drug resistance in AML. Group: Biochemicals. Grades: Highly Purified. CAS No. 630124-46-8. Pack Sizes: 1mg, 5mg. US Biological Life Sciences. | Worldwide |
| At9283 | AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B, JAK2/3, Abl (T315I) and Flt3 (IC50s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo. Uses: Designed for use in research and industrial production. Additional or Alternative Names: 1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)urea;1-Cyclopropyl-3-(3-(5-(morpholinomethyl)-1H-benzo[d]imidazol-2-yl)-1H-pyrazol-4-yl)ureaAT9283;AT9283, >=98%;N-cyclopropyl-N-[3-[5-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]Urea;Urea, N-cyclopropyl-N-[3-[6-(4-morpholinylmethyl)-1H-benzimidazol-2-yl]-1H-pyrazol-4-yl]-. Product Category: Inhibitors. CAS No. 896466-04-9. Molecular formula: C19H23N7O2. Mole weight: 381.438. Purity: 0.997. Density: 1.45. Product ID: ACM896466049. Alfa Chemistry ISO 9001:2015 Certified. | |
| AT9283 | AT9283 is a multi-targeted kinase inhibitor with potent activity against Aurora A/B , JAK2/3 , Abl (T315I) and Flt3 ( IC 50 s ranging from 1 to 30 nM). AT9283 inhibits growth and survival of multiple solid tumors in vitro and in vivo [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 896466-04-9. Pack Sizes: 10 mM * 1 mL; 2 mg; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50514. | |
| AZD2932 | AZD2932 is a new quinazoline ether inhibitor and is a high affinity inhibitor of VEFGR-2 and PDGFR. It has a balanced ~1:1 ratio of activity vs both VEGFR-2 and PDGFR&beta. It is also active on c-Kit and FLT3 with good selectivity on a panel of kinases. Synonyms: AZD2932; AZD 2932; AZD-2932. Grades: >98%. CAS No. 883986-34-3. Molecular formula: C24H25N5O4. Mole weight: 447.49. | |
| BPR1J-097 | BPR1J-097 is a novel potent FLT3 inhibitor with an IC50 of 11?nM. Synonyms: BPR1J097; BPR1J-097; BPR1J 097; BPR1-J097; BPR1 J097; BPR1J097. Grades: >98%. CAS No. 1327167-19-0. Molecular formula: C27H28N6O3S. Mole weight: 516.62. | |
| BPR1J-340 | BPR1J-340 is a potent and selective FLT3 inhibitor with potential anticancer activity. BPR1J-340 was identified as a novel potent FLT3 inhibitor by biochemical kinase activity (IC50 approximately 25 nM) and cellular proliferation (GC50 approximately 5 nM) assays. BPR1J-340 inhibited the phosphorylation of FLT3 and STAT5 and triggered apoptosis in FLT3-ITD(+) AML cells. The pharmacokinetic parameters of BPR1J-340 in rats were determined. BPR1J-340 also demonstrated pronounced tumor growth inhibition and regression in FLT3-ITD(+) AML murine xenograft models. The combination treatment of the HDAC inhibitor vorinostat (SAHA) with BPR1J-340 synergistically induced apoptosis via Mcl-1 down-regulation in MOLM-13 AML cells, indicating that the combination of selective FLT3 kinase inhibitors and HDAC inhibitors could exhibit clinical benefit in AML therapy. Synonyms: BPR1J 340; BPR1J340. Grades: 98%. CAS No. 1395051-72-5. Molecular formula: C29H34N8O3. Mole weight: 542.63. | |
| Cabozantinib | Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET , with IC 50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT , RET , AXL , TIE2 , and FLT3 ( IC 50 =4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: XL184; BMS-907351. CAS No. 849217-68-1. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-13016. | |
| Cabozantinib, Free Base, 99+% | Cabozantinib, also known as XL184, is an orally bioavailable novel tysosine kinase inhibitor of c-MET and VEGF receptor 2 (VEGFR2). It inhibited MET and VEGFR2 with IC50 values of 1.3 nM and 35 pM, respectively. It also inhibited MET-activating kinase domain mutations Y1248H, D1246N, or K1262R with IC50 values of 3.8, 11.8, and 14.6 nM, respectively. It strongly inhibited several kinases that are implicated in tumor pathobiology including KIT, RET, AXL, TIE2, and FLT3 with IC50 values of 4.6, 5.2, 7, 14.3, and 11.3 nM, respectively. In cellular assays, cabozantinib inhibited phosphorylation of MET, VEGFR2, KIT, FLT3, and AXL with IC50 values of 7.8, 1.9, 5.0, 7.5, and 42 [micro]M, respectively. Cabozantinib inhibited tumor angiogenesis, tumor growth and metastasis in cancers with dysregulated MET and VEGFR signaling. Yakes F.M., et al "Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth." Mol. Cancer Ther. 10: 229 Group: Biochemicals. Alternative Names: BMS-907351; XL-184; Cometriq; N- [4- [ (6, 7-Dimethoxy-4-quinolinyl) oxy] phenyl] -N- (4-fluorophenyl) -1, 1-cyclopropane dicarboxamide (2S)-2-Hydroxybutanedioic Acid. Grades: Highly Purified. CAS No. 849217-68-1. Pack Sizes: 25mg, 50mg, 100mg. US Biological Life Sciences. | Worldwide |
| Cabozantinib L-Malate Salt | Cabozantinib is a small molecule C-Met modulator. Cabozantinib acts as a potent multitargeted VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50 of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively. Cabozantinib shows dose-dependent inhibition of tumor growth and tumor regression, associated with disruption of the tumor vasculature and extensive tumor cell apoptosis. Group: Biochemicals. Alternative Names: N- [4- [ (6, 7-Dimethoxy-4-quinolinyl) oxy] phenyl] -N- (4-fluorophenyl) -1, 1-cyclopropane dicarboxamide (2S)-2-Hydroxybutanedioic Acid; Cabozantinib S-Malate; BMS-907351; XL-184; Cometriq. Grades: Highly Purified. CAS No. 849217-68-1. Pack Sizes: 25mg, 50mg, 100mg. US Biological Life Sciences. | Worldwide |
| Cabozantinib S-malate | Cabozantinib S-malate (XL184 S-malate) is a potent multiple receptor tyrosine kinases inhibitor that inhibits VEGFR2 , c-Met , Kit , Axl and Flt3 with IC 50 s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: XL184 S-malate; BMS-907351 S-malate. CAS No. 1140909-48-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-12044. | |
| Cabozantinib (Standard) | Cabozantinib (Standard) is the analytical standard of Cabozantinib. This product is intended for research and analytical applications. Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET , with IC 50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT , RET , AXL , TIE2 , and FLT3 ( IC 50 =4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis [1] [2]. Uses: Scientific research. Group: Signaling pathways. CAS No. 849217-68-1. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-13016R. | |
| CCT241736 | CCT241736 is a potent and orally active and dual FLT3-Aurora inhibitor, which has IC50 values against FLT3, Aurora A and Aurora B of 0.035, 0.015 and 0.1 μM respectively. It also inhibits viability of the human FLT3-ITD positive AML cell lines MOLM-13 with 0.1 μM in cellular assay. Synonyms: CCT-241736; CCT 241736. Grades: ≥98%. CAS No. 1402709-93-6. Molecular formula: C22H23Cl2N7. Mole weight: 456.37. | |
| Cevidoplenib | Cevidoplenib (SKI-O-703) is an orally available inhibitor of spleen tyrosine kinase (Syk) , with potential anti-inflammatory and immunomodulating activities. Cevidoplenib is also the mesylate form of SKI-O-592. Cevidoplenib and SKI-O-592 inhibits BCR-mediated survival, proliferation, and differentiation of B cells. And SKI-O-592 potently inhibits multiple kinases with IC 50 s of 6.2 nM (Syk), 1.859 μM (Jak2), 5.807 μM (Jak3), 0.412 μM (RET), 0.687 μM (KOR), 1.783 μM (FLT3), 16.96 μM (FGFR1), 5.662 μM (FGFR3), and 0.709 μM (Pyk2), respectively [1] [2] [3]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: SKI-O-703. CAS No. 1703788-21-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-109082. | |
| CHMFL-FLT3-122 | CHMFL-FLT3-122 is a potent and selective FLT3 inhibitor (IC50 = 40 nM) with >10-fold and 170-fold selectivity for FLT3 over BTK kinase and c-KIT kinase. It causes apoptosis via cell cycle arrest in G0/G1 phase in vitro. In MV4-11 cell inoculated xenograft model, it suppressed tumor growth. Uses: Antitumor agent. Synonyms: CHMFL-FLT3-122; CHMFL FLT3 122; CHMFLFLT3122; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-(dimethylamino)-ethanone. CAS No. 1839150-56-9. Molecular formula: C26H29N7O2. Mole weight: 471.55. | |
| Crenolanib | Crenolanib is a potent and selective inhibitor of wild-type and mutant isoforms of the class III receptor tyrosine kinases FLT3 and PDGFRα/β with K d s of 0.74 nM and 2.1 nM/3.2 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CP-868596. CAS No. 670220-88-9. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-13223. | |
| Crotonoside | Crotonoside is isolated from Chinese medicinal herb, Croton. Crotonoside inhibits FLT3 and HDAC3/6, exhibits selective inhibition in acute myeloid leukemia (AML) cells. Crotonoside could be a promising new lead compound for the research of AML. Uses: Designed for use in research and industrial production. Additional or Alternative Names: 1,2-Dihydro-2-oxoadenosine. Product Category: Inhibitors. CAS No. 1818-71-9. Mole weight: 283.24. Purity: 95%+. Product ID: ACM1818719. Alfa Chemistry ISO 9001:2015 Certified. Categories: Crotonoideae. | |
| Dovitinib | Dovitinib (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC 50 s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3 , c-Kit , CSF-1R , FGFR1/FGFR3 , VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ , respectively. Dovitinib has potent antitumor activity [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CHIR-258; TKI258. CAS No. 405169-16-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-50905. | |
| Dovitinib Dilactic Acid | Dovitinib is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs with IC50 of 8-13 nM, less potent to InsR, EGFR, c-Met, EphA2, Tie2, IGF-1R and HER2 in cell-free assays. Synonyms: Dovitinib Dilactic acid; TKI258 Dilactic acid; CHIR-258; CHIR 258; CHIR258; TKI258; TKI 258; TKI-258. Grades: >98%. CAS No. 852433-84-2. Molecular formula: C27H33FN6O7. Mole weight: 572.59. | |
| Dovitinib lactate | Dovitinib, also referred as CHIR-258 or TKI258, is a potent receptor tyrosine kinase inhibitor (TKI) that selectively targets VEGFR, PDGFR, FGFR, CSF1R, c-KIT, RET, TrKA, and FLT3, and additionally targets FGFR (IC50 = 5 nM). Synonyms: 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1,3-dihydrobenzimidazol-2-ylidene]quinolin-2-one;2-hydroxypropanoic acid; 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate; Dovitinib(lactate); 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxy; CTK8B6779. CAS No. 692737-80-7. Molecular formula: C24H27FN6O4. Mole weight: 482.51. | |
| Dovitinib lactate | Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC 50 s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3 , c-Kit , FGFR1/3 , VEGFR1/2/3 and PDGFRα/β , respectively [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CHIR-258 lactate; TKI-258 lactate. CAS No. 692737-80-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-10207. | |
| Dovitinib Lactate Hydrate | Dovitinib lactate hydrate is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Synonyms: TKI258 lactate hydrate; CHIR-258 lactate hydrate; 4-Amino-5-fluoro-3-(6-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)quinolin-2(1H)-one 2-hydroxypropanoate hydrate; Propanoic acid, 2-hydroxy-, compd. with 4-amino-5-fluoro-3-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-2(1H)-quinolinone, hydrate (1:1:1). Grades: >98%. CAS No. 915769-50-5. Molecular formula: C24H29FN6O5. Mole weight: 500.52. | |
| Emavusertib | Emavusertib is an orally active inhibitor for IRAK4 ( IC 50 =57 nM) and FLT3. Emavusertib inhibits NF-κB and MyD88 signaling pathways, reduces the generation of pro-inflammatory cytokines like IL-6 and IL-10, thereby exhibiting anti-inflammatory and anti-proliferative activities against cancer cells, leading to cell apoptosis. Emavusertib exhibits antitumor activity in mouse model. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CA-4948. CAS No. 1801344-14-8. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-135317. | |
| FI-700 | FI-700 is a novel and potent FLT3 inhibitor with promising antileukemia activity. FI-700 showed a potent IC(50) value against FLT3 kinase at 20 nmol/L in an in vitro kinase assay. FI-700 showed selective growth inhibition against mutant FLT3-expressing leukemia cell lines and primary acute myeloid leukemia cells, whereas it did not affect the FLT3 ligand (FL)-driven growth of Wt-FLT3-expressing cells. Oral administration of FI-700 induced the regression of tumors in a s.c. tumor xenograft model and increased the survival of mice in an i.v. transplanted model. Furthermore, FI-700 treatment eradicated FLT3/ITD-expressing leukemia cells, both in the peripheral blood and in the bone marrow. Synonyms: FI700; FI 700. CAS No. 866883-79-6. Molecular formula: C21H29N9O. Mole weight: 423.53. | |
| Flonoltinib | Flonoltinib is a potent and orally active dual JAK2/FLT3 inhibitor with IC 50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib has anti-cancer activity [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: JAK2/FLT3-IN-1. CAS No. 2387765-27-5. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-130247. | |
| Flonoltinib TFA | Flonoltinib TFA is a potent and orally active dual JAK2/FLT3 inhibitor with IC 50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. Flonoltinib TFA has anti-cancer activity [1]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: JAK2/FLT3-IN-1 TFA. CAS No. 2928093-29-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg. Product ID: HY-130247A. | |
| FLT3-IN-1 | FLT3-IN-1, a Flt3 inhibitor, has been found to have week activity against T lymphoma Jurkat cells and human lung cancer PC-9 and H292 cells. IC50: 10 nM (in vitro). Uses: Flt3-in-1 is a flt3 inhibitor that has been found to have week activity against t lymphoma jurkat cells and human lung cancer pc-9 and h292 cells. Synonyms: SKLB4771; SKLB-4771; SKLB 4771. FLT3-IN-1; FLT3-IN1; FLT3-IN 1; CHEMBL2046883; SKLB4771; AOB5016; AOB 5016; AOB-5016. Grades: 97%. CAS No. 1370256-78-2. Molecular formula: C25H27N7O3S2. Mole weight: 537.66. | |
| FLT3-IN-17 | FLT3-IN-17 inhibits CYPs and FLT3 mutants activity ( IC 50 s: <0.5 nM for D835Y). FLT3-IN-17 is also a FAK inhibitor, with an IC 50 value of 12 nM. FLT3 ligand-2 can be used in the research of cancers [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2758999-62-9. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-148070. | |
| FLT3-IN-19 | FLT3-IN-19 (Comp 50) is a potent and selective FLT3 inhibitor with IC 50 of 0.213 nM. FLT3-IN-19 can be used in AML disease research [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2237234-48-7. Pack Sizes: 5 mg; 10 mg; 25 mg; 50 mg. Product ID: HY-153473. | |
| FLT3-IN-2 | FLT3-IN-2 is a FLT3 inhibitor with IC50 of ? 1 μM, detailed information refer to WO 2012158957 A2 and WO 2007013896. Uses: Scientific research. Group: Signaling pathways. CAS No. 923562-23-6. Pack Sizes: 10 mM * 1 mL; 1 mg; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-18744. | |
| FLT3-IN-3 | FLT3-IN-3 is a potent FLT3 inhibitor with IC 50 s of 13 and 8 nM for FLT3 WT and FLT3 D835Y , respectively. Uses: Scientific research. Group: Signaling pathways. CAS No. 2229050-90-0. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-112145. | |
| FLT3-IN-4 | FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 ( FLT3 ; IC 50 =7 nM) inhibitor for treating acute myelogenous leukemia [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2304799-09-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-128571. | |
| FLT3-IN-6 | FLT3-IN-6 is a potent and selective inhibitor of FLT3-ITD (FLT3 mutation) with an IC 50 of 1.336 nM [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2377141-31-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-128572. | |
| Fostamatinib | Fostamatinib, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM, strongly inhibiting Syk but not Lyn, and 5-fold less potent to Flt3. Synonyms: R788; R 788; R-788. Grades: >98%. CAS No. 901119-35-5. Molecular formula: C23H26FN6O9P. Mole weight: 580.46. | |
| Fostamatinib sodium | R788 (Fostamatinib) disodium, a prodrug of the active metabolite R406, is a Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 3. Synonyms: R935788. Code names: R788 sodium. R935788 sodium. CAS No. 1025687-58-4. Molecular formula: C23H24FN6O9P.2Na. Mole weight: 624.42. | |
| Gilteritinib | Gilteritinib, also known as (ASP2215, is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations. In invitro, among the 78 tyrosine kinases tested, ASP2215 inhibited FLT3, LTK, ALK, and AXL kinases by over 50% at 1 nM with an IC50 value of 0.29 nM for FLT3, approximately 800-fold more potent than for c-KIT, the inhibition of which is linked to a potential risk of myelosuppression. ASP2215 inhibited the growth of MV4-11 cells, which harbor FLT3-ITD, with an IC50 value of 0.92 nM, accompanied with inhibition of pFLT3, pAKT, pSTAT5, pERK, and pS6. ASP2215 decreased tumor burden in bone marrow and prolonged the survival of mice intravenously transplanted with MV4-11 cells. ASP2215 may have potential use in treating AML. Synonyms: Gilteritinib; ASP2215; ASP-2215; ASP 2215. CAS No. 1254053-43-4. Molecular formula: C29H44N8O3. Mole weight: 552.724. | |
| Gilteritinib | Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3 / AXL inhibitor with IC 50 s of 0.29 nM/0.73 nM, respectively. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ASP2215. CAS No. 1254053-43-4. Pack Sizes: 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-12432. | |
| GTP-14564 | GTP-14564 is a specific kinase inhibitor for ITD-FLT3. GTP-14564 inhibited the growth of interleukin-3-independent Ba/F3 expressing ITD-FLT3 at 1 microM, whereas a 30-fold higher concentration of GTP-14564 was required to inhibit FLT3 ligand-dependent growth of Ba/F3 expressing wild type FLT3 (wt-FLT3). Synonyms: GTP 14564; GTP14564; 1-Phenyl-3-H-8-oxa-2,3-diaza-cyclopenta[a]inden. CAS No. 34823-86-4. Molecular formula: C15H10N2O. Mole weight: 234.25. | |
| HLCL61 | HLCL61 is a potent and selective protein arginine methyltransferase 5 (PRMT5) inhibitor. It is used for treatment of acute myeloid leukemia. It resulted in significantly increased expression of miR-29b and consequent suppression of Sp1 and FLT3 in acute myeloid leukemia cells. Uses: Hlcl61 is used for treatment of acute myeloid leukemia. Synonyms: HLCL-61; HLCL 61; 9-Ethyl-N-[(2-methoxyphenyl)methyl]-9H-carbazole-3-methanamine. Grades: 98%. CAS No. 586395-74-6. Molecular formula: C23H24N2O. Mole weight: 344.19. | |
| HM43239 | HM43239 is an orally active small molecule inhibitor of FLT3 that selectively inhibits not only FLT3 wild type, ITD mutants or TKD mutations, but also FLT3 ITD/TKD double mutations. HM43239 directly inhibits the kinase activity of FLT3 as a reversible Type I inhibitor and effectively modulates downstream p-STAT5 and p-ERK. HM43239 also demonstrated inhibition of SYK, JAK1/2 and TAK1, known to be involved in tumor cell proliferation and/or differentiation HM43239 monotherapy induced dose-dependent regression of tumor growth in FLT3 wild-type and FLT3 mutated leukemia cancer cell line. Uses: Designed for use in research and industrial production. Additional or Alternative Names: HM43239; HM-43239; HM 43239. Product Category: Inhibitors. Appearance: Solid powder. CAS No. 2569527-64-4. Molecular formula: C29H33ClN6. Mole weight: 501.08. Purity: >98%. IUPACName: rel-5-Chloro-N-[3-cyclopropyl-5-[[(3R,5S)-3,5-dimethyl-1-piperazinyl]methyl]phenyl]-4-(6-methyl-1H-indol-3-yl)-2-pyrimidinamine. Canonical SMILES: CC1=CC2=C(C=C1)C(C3=NC(NC4=CC(CN5C[C@@H](C)N[C@@H](C)C5)=CC(C6CC6)=C4)=NC=C3Cl)=CN2. Product ID: ACM2569527644. Alfa Chemistry ISO 9001:2015 Certified. Categories: tuspetinib. | |
| IFN alpha-IFNAR-IN-1 hydrochloride | IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor. It inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3-L-differentiated pDC cultures (BM-pDCs) (IC50=2-8 μM). Synonyms: IFN-alpha/IFNAR-IN-1 hydrochloride. CAS No. 2070014-98-9. Molecular formula: C18H18ClNS. Mole weight: 315.86. | |
| JAK2-IN-7 | JAK2-IN-7 is a selective JAK2 inhibitor with IC 50 s of 3, 11.7, and 41 nM for JAK2, SET-2, and Ba/F3 V617F cells, respectively. JAK2-IN-7 possesses >14-fold selectivity over JAK1, JAK3, FLT3. JAK2-IN-7 stimulates cell cycle arrest in the G0/G1 phase and induces tumor cell apoptosis. Antitumor activities [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2593402-36-7. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-131906. | |
| JNJ-28312141 | JNJ-28312141 is an orally active CSF1R inhibitor (Colony-stimulating factor-1 receptor, CRF1R) and also a FLT3 inhibitor. CSF1R is expressed by many tumors and is a growth factor for macrophages and mediates osteoclast differentiation. JNJ-28312141 represents a new agent with potential therapeutic activity in acute myeloid leukemia and in settings where CSF-1-dependent macrophages and osteoclasts contribute to tumor growth and skeletal events. Synonyms: JNJ28312141; JNJ 28312141; 4-cyano-N-(5-(1-(2-(dimethylamino)acetyl)piperidin-4-yl)-2',3',4',5'-tetrahydro-[1,1'-biphenyl]-2-yl)-1H-imidazole-2-carboxamide. CAS No. 885692-52-4. Molecular formula: C26H32N6O2. Mole weight: 460.58. | |
| KG5 | KG5 is an orally active dual PDGFRβ and B-Raf allosteric inhibitor. KG5 also inhibits Flt3 , KIT and c-Raf. KG5 has anticancer, antiangiogenic activities [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 877874-85-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg. Product ID: HY-15198. | |
| KG 5 | KG 5 is a B-Raf allosteric and PDGFRβ inhibitor. It inhibits FLT3, KIT and c-Raf. It arrests cells in prometaphase and inhibits growth of renal and pancreatic tumors in mice. It also inhibits angiogenesis in a mouse angiogenesis model and disrupts blood vessel formation in zebrafish embryos. It is orally available. Synonyms: KG-5; KG 5; KG5; 2-(Methylthio)-6-[4-[5-[[3-(trifluoromethyl)phenyl]amino]-1H-1,2,4-triazol-3-yl]phenoxy]-4-pyrimidinamine; 2-Methylsulfanyl-6-[4-[3-[3-(trifluoromethyl)anilino]-1H-1,2,4-triazol-5-yl]phenoxy]pyrimidin-4-amine. Grades: ≥98% by HPLC. CAS No. 877874-85-6. Molecular formula: C20H16F3N7OS. Mole weight: 459.45. | |
| KRC-108 | KRC-108 is a multiple kinase inhibitor. KRC-108 is a potent inhibitor of Ron, Flt3 and TrkA as well as c-Met. KRC-108 inhibited oncogenic c-Met M1250T and Y1230D more strongly than wild type c-Met. The anti-proliferative activity of KRC-108 was measured by performing a cytotoxicity assay on a panel of cancer cell lines. The GI(50) values (i.e., 50% inhibition of cell growth) for KRC-108 ranged from 0.01 to 4.22 μM for these cancer cell lines. KRC-108 was also effective for the inhibition of tumor growth in human HT29 colorectal cancer and NCI-H441 lung cancer xenograft models in athymic BALB/c nu/nu mice. This molecule should serve as a useful lead for inhibitors targeting kinases and may lead to new therapeutics for the treatment of cancer. Synonyms: KRC 108; KRC108; 3-(benzo[d]oxazol-2-yl)-5-(1-(piperidin-4-yl)-1H-pyrazol-4-yl)pyridin-2-amine. CAS No. 1146944-35-5. Molecular formula: C20H20N6O. Mole weight: 360.41. | |
| KRN383 | KRN383 is a novel Flt3 inhibitor with potential anticancer activity. KRN383 inhibited the autophosphorylation of Flt3 bearing internal tandem duplications (ITDs) and the Asp835Tyr (D835Y) point mutation with half-maximal inhibitory concentration (IC(50)) values of < or =5.9 and 43 nM, respectively. KRN383 also inhibited the proliferation of the ITD-positive cell lines with IC(50) values of < or =2.9 nM. A single oral administration of 80 mg/kg of KRN383 eradicated ITD-positive xenograft tumors in nude mice and prolonged the survival of SCID mice carrying ITD-positive AML cells. The effectiveness of a single oral dose of KRN383 suggests that it has the potential to be used in a wide variety of clinical regimens, including multicycle and combination therapies. Synonyms: KRN 383; KRN-383. CAS No. 919767-02-5. Molecular formula: C17H17N3O4. Mole weight: 327.34. | |
| Kw-2449 | KW-2449 is a multi-targeted kinase inhibitor of FLT3, ABL, ABLT315I and Aurora kinase with IC50s of 6.6, 14, 4 and 48 nM, respectively. Uses: Designed for use in research and industrial production. Product Category: Inhibitors. CAS No. 1000669-72-6. Molecular formula: C20H20N4O. Mole weight: 332.4. Purity: >99%. Product ID: ACM1000669726. Alfa Chemistry ISO 9001:2015 Certified. | |
| KW-2449 | KW-2449 is a novel multikinase inhibitor, which suppresses the growth of leukemia cells with FLT3 mutations or T315I-mutated BCR/ABL translocation. Recent research showed that HDACIs increase KW-2449 lethality in Bcr/Abl(+) cells in association with inhibition of Bcr/Abl, generation of ROS, and induction of DNA damage. This strategy preferentially targets primary Bcr/Abl(+) hematopoietic cells and exhibits enhanced in vivo activity. Combining KW-2449 with HDACIs warrants attention in IM-resistant Bcr/Abl(+) leukemias. Synonyms: KW2449; KW-2449; KW 2449. CAS No. 1000669-72-6. Molecular formula: C20H20N4O. Mole weight: 332.407. | |
| LBW242 | LBW242 is a Smac mimetic, and potent IAP inhibitor. LBW242 is effective against mutant FLT3 at doses that are physiologically achievable and well tolerated in vivo. LBW242 also enhances the inhibitory effects of PKC412, as well as standard chemotherapeutic agents such as doxorubicin and Ara-c, by acting in an additive-synergistic fashion against mutant FLT3-expressing cells in vitro. LBW242 also sensitizes ovarian cancer cells to the antitumor effects of TRAIL and anticancer drugs commonly used in clinic. Synonyms: N-{(1S)-1-Cyclohexyl-2-oxo-2-[(3aR,7aS)-6-(2-phenylethyl)octahydro-1H-pyrrolo[2,3-c]pyridin-1-yl]ethyl}-N2-methyl-L-alaninamide; Propanamide, N-[(1S)-1-cyclohexyl-2-[(3aR,7aS)-octahydro-6-(2-phenylethyl)-1H-pyrrolo[2,3-c]pyridin-1-yl]-2-oxoethyl]-2-(methylamino)-, (2S)-; (S)-N-((S)-1-cyclohexyl-2-oxo-2-((3aR,7aS)-6-phenethyloctahydro-1H-pyrrolo[2,3-c]pyridin-1-yl)ethyl)-2-(methylamino)propanamide. Grades: ≥95%. CAS No. 867324-12-7. Molecular formula: C27H42N4O2. Mole weight: 454.65. | |
| Lestaurtinib | Lestaurtinib (CEP-701) is an orally active and selective RPTKs (receptor protein tyrosine kinase) inhibitor, competitively inhibits ATP binding to the TrkA/B/C domain. Lestaurtinib inhibits RPTKs phosphorylation, with IC 50 s of 2, 25 and 0.9 nM for FLT3 , TrkA and JAK2 , respectively. Lestaurtinib induces apoptosis and cycle arrest, also can inhibit growth of tumor [1] [2] [3] [4] [5] [6]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: CEP-701; KT-5555. CAS No. 111358-88-4. Pack Sizes: 1 mg; 5 mg; 10 mg. Product ID: HY-50867. | |
| Linifanib | Description of Linifanib: Linifanib is an orally bioavailable, small-molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. This agent does not have a general antiproliferative effect due to its high dose requirement. However, linifanib may exhibit potent antiproliferative and apoptotic effects on tumor cells whose proliferation is dependent on mutant kinases, such as fms-related tyrosine kinase receptor-3 (FLT3). Synonyms: ABT869; ABT 869; ABT-869; Linifanib. CAS No. 796967-16-3. Molecular formula: C21H18FN5O. Mole weight: 375.407. | |
| Linifanib | Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC 50 s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: ABT-869; AL-39324. CAS No. 796967-16-3. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 50 mg; 100 mg; 200 mg; 500 mg. Product ID: HY-50751. | |
| LY2801653 dihydrochloride | LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissociation constant (K(I)) of 2 nM, a pharmacodynamic residence time (K(off)) of 0.00132 min(-1) and t(1/2) of 525 min [1]. LY2801653 was found to have potent activity against several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2. LY2801653 demonstrated in vitro effects on MET pathway-dependent cell scattering and cell proliferation; in vivo anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects. Synonyms: LY-2801653 dihydrochloride; LY 2801653 dihydrochloride. Grades: >98%. CAS No. 1206801-37-7. Molecular formula: C30H24Cl2F2N6O3. Mole weight: 625.45. | |
| MAX-40279 | MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 has the potential for the research of acute myelogenous leukemia (AML) (extracted from patent WO2021180032) [1]. Uses: Scientific research. Group: Signaling pathways. CAS No. 2070931-57-4. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-145723. | |
| Merestinib | Merestinib (LY2801653) is a potent, orally bioavailable c-Met inhibitor ( K i =2 nM) with anti-tumor activities. Merestinib (LY2801653) also has potent activity against MST1R (IC 50 =11 nM), FLT3 (IC 50 =7 nM), AXL (IC 50 =2 nM), MERTK (IC 50 =10 nM), TEK (IC 50 =63 nM), ROS1, DDR1/2 (IC 50 =0.1/7 nM) and MKNK1/2 (IC 50 =7 nM) [1] [2]. Uses: Scientific research. Group: Signaling pathways. Alternative Names: LY2801653. CAS No. 1206799-15-6. Pack Sizes: 10 mM * 1 mL; 5 mg; 10 mg; 25 mg; 50 mg; 100 mg. Product ID: HY-15514. | |
Our database is helping our users find suppliers everyday.
